About This Video
We start our second show of the season by revisiting one of the most memorable interviews from last season with Ilan Sobel, CEO of BioHarvest Sciences (CSE:BHSC). On last year's interview we learned about the driving mission of his company to build "human utility value". We use that as a jumping-off point as we re-unite after a notable year for the company despite global and economic headwinds.
Ilan provides an update on BioHarvest's two key product verticals in the Polyphenol and Cannabis sectors, and how each are taking unique (and in some cases, similar) paths to market. Ilan also reflects on some of the choices the company has made with respect to developing its sales funnel and shares valuable lessons about acting as a "learning" organization and listening to your customers.
Mr. Sobel is Chief Executive officer of BioHarvest Sciences Inc. (CSE:BHSC) - the developer and exclusive owner of the proprietary and patent-protected BioFarming technology. It is the first and only industrial-scale plant cell technology capable of producing the active plant ingredients without the necessity to grow the plant itself. The Company’s technology is non-GMO and has already been validated by VINIA, the red grapes cells functional food/dietary supplement produced and sold by BioHarvest Sciences Inc.
The Company plans to generate significant revenue within the global nutraceutical ingredients and dietary supplements market with VINIA and other Super Fruit Nutraceutical products. Further, by adapting this technology to the Cannabis plant, and building adequate production capacity, BioHarvest Sciences Inc.’s objective is to become a leading supplier of Cannabis for both medicinal and legal recreational purposes.
Visit: www.bioharvest.com
Host: James Black
Producer: James Black
Guest: Ilan Sobel
Subscribe for more great CSE insights and interviews here: https://go.thecse.com/CSETV-Subscribe
STAY CONNECTED WITH THE CSE
=============================
- NEWSLETTER: https://go.thecse.com/CSE-Mailing-List-Subscribe
- PODCAST: https://blog.thecse.com/cse-podcasts/
- INSTAGRAM: https://www.instagram.com/canadianexchange/
- LINKEDIN: https://ca.linkedin.com/company/canadian-securities-exchange
- FACEBOOK: https://www.facebook.com/CanadianSecuritiesExchange/
- TWITTER: https://twitter.com/CSE_News
- BLOG: https://blog.thecse.com/
- WEBSITE: https://thecse.com/
- MAGAZINE: https://issuu.com/thecse/docs
Read the Transcript
all right well welcome back to the show this is James Black your host and I'm with you and Sobel CEO of bioharvest Sciences all the way from Israel now Atlanta is a repeat guest he was with us a year ago on the show to talk about bioharvest and what they were working on but a year ago feels like 10 years ago maybe just describe me because
we were in the midst of Delta I mean the variant that was running its course and I can imagine last year just basically press releases and your updates A lot's happened so maybe just try to paint a picture for our viewers who maybe were there for us with us a year ago what's happened in the last year just some broad strokes and we'll go a bit deeper from there afterwards well look you know by Harvest had an absolute cracker of a year
in 2022 and that's just because we are super focused on executing our strategy and over delivering on the guidance that we're giving our shareholder Partners in in 2022 the big the big wins for the business really were on our polyphenol antioxidant vertical as everybody knows by Harvest is a biotech company where the global leaders in plant cell biology we are we are a company that has platform technology and the platform technology today
we operate in two verticals polyphenol antioxidant vertical and soon to be James cannabis vertical so in each of these critical areas we we really had some significant achievements in our polyphenol antioxidants vertical where we delivered north of 5.6 million dollars of Revenue worth literally one SKU which is our veneer unique veneer polyphenol antioxidant red grave cell proposition our biggest achievement really was around scaling the business in
North America massive scaling that we started the third week of August starting with TV advertising supported by social media and literally recruited north of 21 000 new customers on video in that short period of time and that was supported by the scaling efforts of our manufacturing organization as you know we have recently opened our new 25 plus ton facility for four and a half million dollars we produced a facility that a one-time investment I should say of roughly
44.5 million dollars we have opened a facility that can produce roughly 25 tons of vinia every single year and that facility was up and running and and really James it's just been hand to mouth the entire period to deal with the the you know overwhelming demand that we've received from U.S and Canadian customers and since we started to scale the marketing efforts of the business and and really I I guess we're not surprised just given you know the demand
but you know as a result of just the feedback we're getting around the overall efficacy and the impact of Vineyard which is backed by clinical trials all double-blind Placebo and that's why we have a rating of 4.8 out of five a verified rating of 4.8 out of 5 and and I I really I suggest to all your listeners to go to our website go to video.com have a look at
our website have a look at the reviews read the reviews and you'll see the you know significant positive impact that we're having on people's overall health and wellness so it was a big year for vinya it was a big year for the scale up and 2023 is just 3xing it again you know that's all we do here with 3x you know in 2022 we 3x 2021 and 2023 the plan is to once
again on video to 3x and then in addition we will be bringing to the North American Market a grade of cannabis that the market has never seen before with a unique blend of cannabinoids that we're bringing to the market which we shared to our investor Partners about two three months ago and that's a big Focus for us in the second half of the year to start to execute and operationalize our three-prong cannabis strategy but 2022 was a huge year for
us from a cannabis commercialization perspective where we started off by demonstrating to the world how we broke biological barriers how we made biological history by being the only company in the world that can grow trichomes in liquid media in fact James we grow 93 trichomes these are our dry trichomes here Elaine went to trichome what's a trichome great question a tricum is a mini Factory in the cannabis plant that actually sits on the
outside of the plant and it's the mini Factory that produces the cannabinoids the terpenes and the flavonoids and with our technology we figured out how to literally in massive bioreactors how to grow cells of the cannabis plant and then to get these cells to grow trichomes these mini factories and over literally a three-week period where we're in continuous flowering which in a normal traditional indoor agricultural cycle will take anywhere from 12 to 16 weeks we do
it in three weeks and each one of our bioreactors which is you know I'm I'm gonna explain that to me what's a bioreactor as well that was one of my prep questions okay well what is a bioreactor is it petri dish or is it something else it it all starts in a Petri dish okay that's our process and we have this unique capability to get out of the petri dish and to just do massive scaling
into large-scale bioreactors where the cells are suspended in liquid media now we're controlling all the critical variables that are so important for the overall growth and development of the cell and the elicitation of the cell in the case of cannabis to produce trichomes and then for the trichomes to produce the different cannabinoids so we're controlling all these critical variables so that after three weeks we have 93 trichomes material 93 trichome material that's then dried
all right and ready to go to market whether it's to be smoked Vaped just consumed in a capsule there's you know multiple different you know consumption routes that our material is able to perform so it was a Monumental year for us because we were able to be the first company in the world to be able to grow trichomes in liquid media and then we were able to demonstrate as well
in 2022 the unique composition of our trichomes getting to 36 cannabinoids we took a hemp plan for three percent cannabinoids and we moved it up to 36 percent with very significant levels of CBD THC and the varins like cbdv thcv which you know you know today sell for 30 40 000 a kilo we have high levels of that in our composition so you know it was Major a major year
for us from a manufacturing scale a major year for us as far as building the commercial machine to be able to sell vignette direct to Consumer and direct to doctor which are our two critical channels and a major year for us in cannabis commercialization which right now we're busy double Downing on to bring our cannabis portfolio of products to Market in the second half of 2023. okay that that the raises a question for me then so did you guys learn some things
through the commercialization process avenia that you're now going to apply to your cannabis execution strategy for commercialization is there something you can you can report from that to this that's a great question and you know we pride ourselves on being a learning organization and so where there are learnings we need to make sure we're stepping back and looking at those learnings I think you know there are a number of synergies
between our call it our cannabis our cannabis Scout up and our Vineyard scale up those synergies exist really in in two major areas firstly manufacturing okay whatever improvements we do in driving scalability in driving overall cost improvements on our on our technology because it's a platform technology cost savings that I drive on video and we really focus on doing that they literally go straight across into cost savings on cannabis which which is why
we can produce cannabis today we believe at at by far their the be the best cost per kilo at scale versus all other players in the North American Market so manufacturing there's a lot of learnings the other area where there are learnings from a I would call a consumer and a route to Market perspective is on the e-commerce site you know in the last 18 months we have an
amazing team of marketing team and Commercial and e-commerce team we built an e-commerce machine e-commerce demand and selling machine demand creation and selling machine which has just done an amazing job bringing people at the top of the funnel and moving them very quickly down into a conversion with conversion rates that are best in the industry whether it's Amazon or whether it's our own vineyard.com site so so with those
with those learnings what it means now is with you know a customer base of Norfolk 25 000 customers I have with and growing by thousands every single month we're laying the pipes into the North American market for us to layer on other products so one of our core strategies in the broader cannabis strategy is entering into the market with unique hemp Plus premium products with unique hemp-based cannabinoid or Blends that the market has not seen before that obviously in the
in the U.S market it's federally legal CBD plus and therefore we can push it through the same e-commerce machine and start to really leverage those learnings similarly we're also developing products which bring the power of our cannabis proposition together with the power of our polyphenol antioxidant world because they go so well together in addressing a number of critical health and wellness indications so where there's Synergy and learnings we maximize in other areas
whether or not you know obviously we we have to you know go through the learning curves right so why why do you guys want to be in the cpg side of things and integrate that far down the chain is it I mean I'll let you answer it but to me I mean it seems like you could have just licensed out the technology or wholesale sold it but you've decided to go direct a customer
what what motivated you to do that knowing full well your experience in a past life at Coca-Cola but it's actually a great question so the choice you know in in rats to Market you have many different models you know you have classic B2B models right being more of an industrial product an ingredient you have direct to Consumer and you know we had to make some choices now
we've decided to basically go in the case of vineya to go with a strategy which is direct to Consumer oriented and I think that was the best decision that we made back nearly three years ago in Israel when we first launched Vineyard and in our first month in Israel our first full month in Israel we did roughly a hundred thousand US dollars in little Israel of of sales orders
and I really realized the power of going direct because you're able to control the entire consumer experience you're building brands you're maximizing margins remember we're in business to change people's lives but ultimately we've got to earn a good return for our shareholder Partners so your margin optimization is there when you go direct to Consumer you could do that efficiently and then there's the gift Factor and so James what I mean by the gift Factor the gift factor
is really around direct to Consumer you get direct opportunity to get feedback from your consumers yeah right whether it's emails to you whether it's actual verified customer reviews whether it's on the phone through your customer call center and and that's really why today from feedback you know and understanding our customer base exceptionally well we realized after being in in this business for two years that vineya as a product was delivering significant
benefits outside of our core cardiovascular claim areas which are driven off the clinical trials that we've done in the cardiovascular space and what we realized was the blood flow opportunity was so much greater given consumer needs around addressing major health and wellness challenges all related to blood flow for example we learned that there are many of our customers that are utilizing vineya for health awareness conditions linked to linked to linked to blood flow that
we don't talk about because our clinical trials are not in that area I'll give you an example erectile dysfunction we understand today and you can see it on Facebook many people call us the purple pill because at the end of the day our clinical trials demonstrated that after taking one capsule of Vineyard and in one capsule we have the same all the benefits of one bottle of red wine no
sugar no calories no alcohol and the key benefits are derived by the past from the past seed Resveratrol and in one capsule you have the same amount of Pisces Resveratrol as one bottle of red wine no sugar no calories no alcohol plus a matrix of other polyphenols including catagen coercity anthocyanins and tannins with amazing solubility and bioavailability what we realized is that as a result of our clinical trials which showed our ability to increase the dilation
of one's arteries by 70 versus Baseline after taking one capsule every day for 90 days and with that increasing dilation of your arteries you have way more blood flow in your body and the more blood flow the more oxygen and more nutrients going to the body's tissues and organs so we started to get feedback that wow this product is amazing to address qualit sexual performance or erectile dysfunction depending if you're coming in from a dietary supplement site
right or you know a disease side and we started to understand that consumers were using it for that benefit we started to realize consumers were using it for gingivitis gingivitis is a lack of blood flow to the tissue around your teeth we started to realize that consumers were getting amazing benefits from vinya as a result of reynards Reynard syndrome Reynolds syndrome is a lack of blood flow to your fingertips into your toes so we started to realize wow the size
of the prize and the opportunity isn't just around cardiovascular health and energy where we focused and if you go to our website today that's all we talk about all right and now it's a huge space in the US that's you know roughly a 10 billion dollar opportunity but that opportunity could be extended with more clinical trials based on the amazing figure back this gift going back to the gift of feedback from consumers when we were realizing that our product was working in
so many different areas that you know we hadn't really considered before so as we move forward in 2023 we're now going to do the required clinical studies to be able to demonstrate with empirical evidence the benefit of our product in these areas and then based on this we will decide whether we have how we leverage these learnings into either new products or additional claims we start to make on Vineyard or even potentially to move up to look at the Botanical drug route
you know if we see that the the studies are really able to deliver transformational results across the different indications that we're going to be going to be looking at so it's super exciting so see you can see we're operating as a supplement we can move up as well into the Botanical drag area again an area we're starting to really understand and spend a lot more time but the good news is the Hardcore Revenue comes from the dietary supplement because
that's Revenue today and tomorrow obviously on the Botanical drug side it's a longer period of time and it's a longer bet so in our financials and our projections we don't even look at that that's like cream on you know icing Icing on the Cake also our B2B business we do have a very strategic B2B business with our partner bittori Foods who's the largest food ingredients distributor in North America an amazing company and we've developed a very clear strategic architecture of
specific categories and customers we're willing to actually partner with from a long-term perspective because obviously we want to partner as a Intel Insight in certain areas which are complementary to our dietary supplement business we don't want to do anything that's going to be cannibalistic to our existing supplement business yeah beautiful stuff and and obviously just a little lesson at the beginning of that about you know parsing through data and avoiding confirmation bias so
you actually can find new sales opportunities if you take a wider look at what it is your product is doing for customers I think that's really important the unintended consequence is of what that product could be doing for your business is you got to have your blinders open you can't have your mind close to that and that's about being willing to hear the feedback I'm sure some of the feedback you got over the over the time wasn't all positive
and you know you have to be okay with that as well right one of the one of the deep beliefs I have and just kind of I guess a learning yeah learning and some people think I'm crazy about this but that's fine I'm happy for them to tell me crazy is that you know when you're building a business that's so transformational with the technology that we have
you cannot Outsource your customer success side of the business because you have to be at the cold face at that moment of truth with the end consumer or the End customer you have so many of these companies out there that you know basically you know they produce and they Outsource and they end up Outsourcing so many of these functions you know we we have an amazing customer success team
led by by Jackie and and this team and she really now has you know we have a large customer base so we have a significant a significant team they're at the coal face of the business and the feedback that we get is tremendous as it relates to our us business in Israel here we have an amazing team led by Michael and itai and with with with the ability in the case of Israel
we actually also sell a lot over the phone the Israeli Market's a little bit different we do about 60 of our sales over the phone so we're talking directly with customers and we know for every single customer and it's logged into our systems exactly why they're utilizing the product how they use the product and again it's this feedback it's this triangulation of data that really helps you understand the opportunities and to be able to really scale your product by making
sure that one product is delivering on multiple different benefits of the consumer and having that interaction so if if there is ever a need to engage you have that direct ability all the time yeah I want to ask you about Israel so from the Cannabis perspective and its role globally is Israel a place where great Technologies are developed and then it's used as a Proving Ground or do you see it playing a different or bigger role in the Cannabis space globally
so you know Israel I guess in the case of cannabis is a little bit different to other Industries in the previous life I was high tech so literally from a high-tech perspective everything you know in all the areas that Israel is really strong in high tech and basically the r d is all done here and then you know given the size of the market literally you know all the pilot studies
and the scaling happens outside of Israel right and in fact there are many Israeli companies that literally do massive exits and they haven't sold one check or inside Israel all right yep cannabis is a little bit different because a couple things firstly you know cannabis has an enormously Rich Heritage here in Israel in Israel Professor Rafi mosholam you know in the late 70s early 80s discovered the endocannabinoidal system and as a result there's
really a I guess a real pioneering Spirit in in the medicinal cannabis space here in Israel and to be able to really push push boundaries whether it's you know in the area where we are which is you know basically the Botanical space or in you know synthetic or you know or a biosynthesis this you have you have the whole Spectrum here in Israel and and you know just given the rich history you have and the infrastructure you have that
you have a lot of breakthrough breakthrough Technologies coming out of Israel at the same time the Israeli Market is a decent sized Market you have 120 000 medicinal cannabis users here the Israeli mindset is is I guess more open-minded from an integrative Medicine perspective then the more traditional markets so you you do have the opportunity in Israel to very much test and learn and then scale and it's a great laboratory a testing and learning laboratory with
a significant Market to have scale and then to just you know get success and massively scale outside of Israel yeah that's a great insight and having done business there I can I've seen it firsthand in fact I will be visiting you very soon hopefully march to see firsthand at our state-of-the-art GMP facility obviously no cameras we'll have to we'll have to search you you know Israeli Style just to make sure that you're not not my first time reading on our IP
or anything like that but we look forward to having the opportunity to host you okay well that's that's great you know what Elaine I'm gonna leave it there I think there's gonna be more interviews this is there's a lot to bite off with your company bioharvest Sciences bhsc on the CSC and obviously a lot more to come in the coming year hopefully there's not so many
deviations in the global market as far as conflict and disease we can just get down to business and get things done so once again thanks for joining us on the csc's exchange for entrepreneurs podcast and once again this is James Black your host thanks so much for watching foreign



